Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.
1. A process for preparing vortioxetine hydrobromide propylene glycol solvate form AC1 comprising the steps of:
a. combining vortioxetine hydrobromide and propylene glycol to obtain a solution of vortioxetine hydrobromide in propylene glycol;
b. maintaining the solution of step a) at a temperature of about 0° C. to about 150° C.; and
c. isolating vortioxetine hydrobromide propylene glycol solvate form AC1.
2. Crystalline vortioxetine hydrobromide propylene glycol solvate form AC1 characterized by data selected from: an x-ray powder diffraction pattern with peaks at about 19.82, 20.97, 23.06, 25.7, 29.77±0.2 degrees 2-theta; an x-ray powder diffraction pattern with peaks substantially as depicted in FIG. 1 ; or a combination thereof.
3. Crystalline vortioxetine hydrobromide propylene glycol solvate form AC1 characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.
4. Crystalline vortioxetine hydrobromide propylene glycol solvate form AC1 characterized by an x-ray powder diffraction pattern with peaks substantially as depicted in FIG. 3 .